Clinical Trials Browser

Phase 2/3 × Has announcements × Nivolumab × Clear all

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 1 FDA

Melanoma, Neoplasms